EVIDENCE. COMPARISONS. CLEAR NEXT STEPS.FOR US CLINIC TEAMS PROCUREMENT RESEARCH
SECTION 04 OF 12 / Monitor

Regulatory news and changes

Track dated changes and the actions they require.

17Pages
56Sources cited
18 Nov 2026Last updated
Pharmacy reference binders and regulatory paperwork on a clinical counter
THE CHANGE BOARD

What changed. Who acts next.

FDAconfirmed

FDA requires GLP-1 labelling changes concerning a potential increased risk of nonarteritic anterior ischemic optic neuropathy, or NAION.

Who should act: All clinical programmes and dispensing partners

IMMEDIATE ACTION

Medical director: review counselling, escalation and partner materials. (fda.gov)

Read the research →
FTCconfirmed

FTC’s Hims & Hers case records an amended complaint; five additional states joined the privacy and billing litigation. These remain allegations, not adjudicated findings.

Who should act: Telehealth platforms, subscription clinics and integrated access vendors

IMMEDIATE ACTION

Compliance: review data sharing, charging triggers and cancellation workflows. (ftc.gov)

Read the research →
HHSproposed

HHS publishes notice of a draft/interim enforcement-discretion policy for specified peptide substances—not a general GLP-1 compounding permission.

Who should act: Clinics receiving peptide-expansion proposals

IMMEDIATE ACTION

Counsel: reject extrapolation beyond the substances and conditions actually listed. (govinfo.gov)

Read the research →
FDAconfirmed

FDA’s Empower Pharmacy warning letter challenges apparently copied GLP-1 preparations and supporting patient-difference documentation.

Who should act: Clinics relying on patient-specific compounding

IMMEDIATE ACTION

Audit prescribing templates and evidence supporting formulation changes. (fda.gov)

Read the research →
Fifth Circuitconfirmed

Fifth Circuit opinions affirm judgments supporting FDA’s tirzepatide and semaglutide shortage decisions.

Who should act: Buyers relying on litigation to preserve shortage-era supply

IMMEDIATE ACTION

Require the actual order behind any claimed litigation protection. (ca5.uscourts.gov)

Read the research →
FDAconfirmed

FDA letter addresses compounded GLP-1 multidose-vial labelling, dosing confusion and use beyond the customary post-puncture period.

Who should act: Clinical, procurement and finance teams

IMMEDIATE ACTION

Reconcile vial size, discard instructions and usable supply before accepting quotes. (azbn.gov)

Read the research →

Confirmed denotes the occurrence of the dated event in the supplied research, not the adjudication of allegations or approval of a supply route. These remain allegations, not adjudicated findings.

Read the research

15 pages shown

Research quality self-assessment
9 / 10buyer fit
9 / 10depth
9 / 10search terms
9 / 10sources

The research’s own assessment; not an external rating.